Briacell Therapeutics
BCTX
23 hedge funds and large institutions have $15M invested in Briacell Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 1 closing their positions.
1,793% more call options, than puts
Call options by funds: $4.6M | Put options by funds: $243K
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
28% more funds holding
Funds holding: 18 → 23 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 0.11% → 0.11% (-0.01%)
12% less capital invested
Capital invested by funds: $17M → $15M (-$2.03M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$166K |
| 2 |
MG
Marex Group
London,
|
+$144K |
| 3 |
OBWG
Onyx Bridge Wealth Group
Tarrytown,
New York
|
+$144K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$78.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$71.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$1.18M |
| 2 |
N
Natixis
Paris,
France
|
-$350K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$156K |
| 4 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$20.8K |
| 5 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$8.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $70 | – | – | – |
|
|
KPF
27
K2 Principal Fund
Toronto,
Ontario, Canada
| – | -$156K | -166 | Closed |
|
28
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$206 | – | – |
|
BCTX Hedge Fund Activity: Q4 2023 in Review
23 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q4 2023, worth a combined $15M — down 12% from $17M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCTX positions and 1 closed out — a net gain of 5 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $166K. The largest seller was Wasatch Advisors, cutting an estimated $1.18M.
- 23 institutional investors held Briacell Therapeutics (BCTX) as of Q4 2023, up from 18 in Q3 2023.
- Funds reported $15M of Briacell Therapeutics stock for Q4 2023, down 12% quarter-over-quarter.
- 6 funds opened new Briacell Therapeutics positions in Q4 2023 and 1 closed out, a net change of +5 holders.
- The largest Briacell Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $166K added.
- The largest Briacell Therapeutics seller in Q4 2023 was Wasatch Advisors, an estimated $1.18M sold.
Based on aggregated 13F filings for Q4 2023.